Tandem Diabetes Care (TNDM) Gross Profit (2016 - 2026)
Tandem Diabetes Care filings provide 13 years of Gross Profit readings, the most recent being $167.5 million for Q4 2025.
- On a quarterly basis, Gross Profit rose 6.35% to $167.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $546.0 million, a 11.53% increase, with the full-year FY2025 number at $546.0 million, up 11.53% from a year prior.
- Gross Profit hit $167.5 million in Q4 2025 for Tandem Diabetes Care, up from $134.3 million in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $167.5 million in Q4 2025 to a low of $73.3 million in Q1 2021.
- Median Gross Profit over the past 5 years was $103.2 million (2022), compared with a mean of $109.6 million.
- Biggest five-year swings in Gross Profit: surged 69.98% in 2021 and later fell 19.24% in 2023.
- Tandem Diabetes Care's Gross Profit stood at $113.7 million in 2021, then rose by 1.58% to $115.5 million in 2022, then fell by 19.24% to $93.3 million in 2023, then surged by 68.77% to $157.5 million in 2024, then rose by 6.35% to $167.5 million in 2025.
- The last three reported values for Gross Profit were $167.5 million (Q4 2025), $134.3 million (Q3 2025), and $125.9 million (Q2 2025) per Business Quant data.